ArticleViruses2025
Burden and Characteristics of RSV-Associated Hospitalizations in Switzerland: A Nationwide Analysis from 2017 to 2023.
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Forecasting the Multidimensional Burdens of Hospital Admissions in LRTIs and COPD: Projections of Healthcare Expenditures, Resource Utilization, and Socioeconomic and Environmental Outcomes for Switzerland.Infectious diseases and therapy · 2026Article
- Economic Burden of RSV-Associated Hospitalizations in Switzerland: A Nationwide Analysis (2017-2023).Healthcare (Basel, Switzerland) · 2026Article
- Article
- Association Between Long-Term Glycemic Control and Clinical Outcomes in Patients With Diabetes Mellitus Hospitalized for Lower Respiratory Tract Infections: A Retrospective Cohort Study.Journal of diabetes research · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) is a major cause of respiratory illness, particularly in children, yet its burden in adults-especially in older adults-remains under-recognized. We analyzed RSV-related hospitalizations in Switzerland from 2017 to 2023 using national data from the Federal Statistical Office, including cases with RSV coded as either a primary or secondary diagnosis. Over 35,000 RSV-related hospitalizations were recorded. The highest incidence occurred in children under 10 years (390 per 100,000/year), with a second peak in adults ≥ 80 years (151 per 100,000/year). Older adults (≥60 years) accounted for more than 9700 hospitalizations overall, with an average of over 16,600 total hospital days per year. Average length of stay (LOS) was shortest in young children (4.6 days) and highest in adolescents (13.9 days), while in adults, it increased from 6.8 days (age 20-29) to 12.3 (age ≥ 80). Mechanical ventilation rates peaked at 12.6% in 60-69 year olds, and in-hospital mortality at 7.1% in those ≥80 years. In adults, RSV was more often recorded as a secondary diagnosis and commonly associated with chronic comorbidities, including chronic obstructive pulmonary disease, heart failure, kidney disease, and diabetes. Frailty-related diagnoses-such as cognitive or motor impairment, delirium, and need for nursing care-were also frequent. These findings highlight the importance of improved adult RSV surveillance and targeted prevention strategies in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.